Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia

Neuropsychopharmacology

Volumn 38, Issue 10, 2013, Pages 1864-1870

  Ikeda, Masashi ^a   Okahisa, Yuko ^b   Aleksic, Branko ^c   Won, Mujun ^d,e   Kondo, Naoki ^d,f   Naruse, Nobuya ^d,g   Aoyama Uehara, Kumi ^h   Sora, Ichiro ^d,i   Iyo, Masaomi ^d,j   Hashimoto, Ryota ^k,l   Kawamura, Yoshiya ^m   Nishida, Nao ⁿ   Miyagawa, Taku ⁿ   Takeda, Masatoshi ^k   Sasaki, Tsukasa ^o   Tokunaga, Katsushi ⁿ   Ozaki, Norio ^c,d   Ujike, Hiroshi ^b,d   Iwata, Nakao ^a,d  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Japanese Genetic Initiative for Drug Abuse ^*  (Japan)

^e Kojin Hospital   (Japan)

^f Seimei Hospital   (Japan)

^g Saitama Prefectural Psychiatric Hospital   (Japan)

^h Serigaya Hospital   (Japan)

ⁱ TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l OSAKA UNIVERSITY   (Japan)

^m Sakae Seijinkai Hospital   (Japan)

ⁿ UNIVERSITY OF TOKYO   (Japan)

^o UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

genome wide association study; methamphetamine; polygenic component analysis; schizophrenia; substance use disorder; substance induced psychosis

Indexed keywords

METHAMPHETAMINE; SARCOGLYCAN;

ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHAMPHETAMINE DEPENDENCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

ALLELES; AMPHETAMINE-RELATED DISORDERS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; METHAMPHETAMINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOSES, SUBSTANCE-INDUCED; SCHIZOPHRENIA;

EID: 84882448118     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.94     Document Type: Article

References (28)

1. Bousman CA, Glatt SJ, Everall IP, Tsuang MT (2009). Genetic association studies of methamphetamine use disorders: a systematic review and synthesis. Am J Med Genet B Neuropsychiatr Genet 150B: 1025-1049.
2. Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G et al (2012). Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry 169: 389-396.
3. Chen CK, Lin SK, Sham PC, Ball D, Loh el W, Murray RM (2005). Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet 136B: 87-91.
4. Cirulli ET, Goldstein DB (2010). Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 11: 415-425.
5. Clark SL, Adkins DE, Aberg K, Hettema JM, McClay JL, Souza RP et al (2012). Pharmacogenomic study of side-effects for antidepressant treatment options in STAR+D. Psychol Med 42: 1151-1162.
6. Grelotti DJ, Kanayama G, Pope HG Jr. (2010). Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literature. Am J Psychiatry 167: 17-23.
7. Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, Sachs GS et al (2010). Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry 167: 1254-1263.
8. Ikeda M, Aleksic B, Kinoshita Y, Okochi T, Kawashima K, Kushima I et al (2011). Genome-wide association study of schizophrenia in a Japanese population. Biol Psychiatry 69: 472-478.
9. Ikeda M, Aleksic B, Yamada K, Iwayama-Shigeno Y, Matsuo K, Numata S et al (2012). Genetic evidence for association between NOTCH4 and schizophrenia supported by a GWAS follow-up study in a Japanese population. Mol Psychiatry (in press).
10. Kristiansen LV, Beneyto M, Haroutunian V, Meador-Woodruff JH (2006). Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry 11: 737-747 705.
11. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K et al (2009). Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 14: 804-819.
12. Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM et al (2010). A versatile gene-based test for genome-wide association studies. Am J Hum Genet 87: 139-145.
13. Machiyama Y (1992). Chronic methamphetamine intoxication model of schizophrenia in animals. Schizophr Bull 18: 107-113.
14. Macintyre G, Alford T, Xiong L, Rouleau GA, Tibbo PG, Cox DW (2010). Association of NPAS3 exonic variation with schizophrenia. Schizophr Res 120: 143-149.
15. MacLaren EJ, Charlesworth P, Coba MP, Grant SG (2011). Knockdown of mental disorder susceptibility genes disrupts neuronal network physiology in vitro. Mol Cell Neurosci 47: 93-99.
16. Miyagawa T, Kawashima M, Nishida N, Ohashi J, Kimura R, Fujimoto A et al (2008). Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 40: 1324-1328.
17. Nutt DJ, King LA, Phillips LD (2010). Drug harms in the UK: a multicriteria decision analysis. Lancet 376: 1558-1565.
18. Otowa T, Yoshida E, Sugaya N, Yasuda S, Nishimura Y, Inoue K et al (2009). Genome-wide association study of panic disorder in the Japanese population. J Hum Genet 54: 122-126.
19. Pickard BS, Christoforou A, Thomson PA, Fawkes A, Evans KL, Morris SW et al (2009). Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder. Mol Psychiatry 14: 874-884.
20. Pieper AA, Wu X, Han TW, Estill SJ, Dang Q, Wu LC et al (2005). The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. Proc Natl Acad Sci USA 102: 14052-14057.
21. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904-909.
22. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
23. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF et al (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460: 748-752.
24. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D et al (2009). Common variants conferring risk of schizophrenia. Nature 460: 744-747.
25. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS et al (2008). Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 13: 570-584.
26. Uhl GR, Drgon T, Liu QR, Johnson C, Walther D, Komiyama T et al (2008). Genome-wide association for methamphetamine dependence: convergent results from 2 samples. Arch Gen Psychiatry 65: 345-355.
27. Ujike H, Sato M (2004). Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 1025: 279-287.
28. Yang J, Lee SH, Goddard ME, Visscher PM (2011). GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 88: 76-82.